The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.
The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

Start Date23 Nov 2023

Sponsor / Collaborator

South Australian Health & Medical Research Institute Ltd.

[+5]

CTRI/2023/05/053005 / CompletedNot Applicable

A randomized controlled trial to evaluate the efficacy of 2% Mupirocin vs 0.5% Neomycin vs placebo intranasal ointment on prevention of surgical site infections among adult patients undergoing cardiac surgery in AIIMS, New Delhi

Start Date01 Jul 2023

Sponsor / Collaborator-

NCT05779254 / RecruitingNot ApplicableIIT

Analysis of Mechanism on the Efficacy of Oral Antibiotic Prophylaxis in Elective Colon and Rectal Surgery With Primary Anastomosis

The microbiome, the collection of microorganisms that live in our gut, plays an important role in maintaining our health, proper nutrient absorption, nutrient turnover and immunity. After birth, a symbiotic relationship develops with the strains of bacteria that colonise our gut, and the presence and proportion of bacteria is individualised and highly variable.
A healthy bacterial flora is essential for the cells of the intestinal mucosa. Glycoproteins in the cell surface mucus coat are important nutrients for bacteria, while some bacterial strains supply mucosal cells with nutrient molecules (e.g. short-chain fatty acids) that are their essential energy source.
An abnormal change in the proportion of bacterial strains that make up the microbiome, dysbacteriosis, in which pathogenic bacteria proliferate at the expense of members of the normal flora, can cause a number of pathologies. Nutrient supply to the cells of the mucosa is reduced, making them more vulnerable and leading to various pathological conditions.
The microbiome and the essential nutrients they produce have also been found to play an important role in wound healing. A decrease in the diversity of the microbiome, an increase in the relative number of pathogenic bacteria and a decrease in the proportion of 'beneficial' bacteria increases the risk of surgical complications of infection and suture failure.

Start Date01 Feb 2023

Sponsor / Collaborator

University of Debrecen

100 Clinical Results associated with Neomycin Sulfate

100 Translational Medicine associated with Neomycin Sulfate

100 Patents (Medical) associated with Neomycin Sulfate

7,725

Literatures (Medical) associated with Neomycin Sulfate

01 Feb 2025·Food Chemistry

Multiplex immunochromatographic test strip based on multicolor gold nanoparticles for the simultaneous detection of neomycin, penicillin, and chloramphenicol in food samples

Article

Author: Arsawiset, Supattra ; Teepoo, Siriwan ; Cheubong, Chehasan

In this study, we demonstrated an approach for the development of multiplex immunochromatographic test strip (MICS) for neomycin (NEO), penicillin (PEN), and chloramphenicol (CAP) detection using three different-colored gold nanoparticles. The gold nanoparticles: gold nanospheres (red), gold nanostars (blue), and gold nanoflowers (black) were applied as labels for MICS fabrication. The proposed MICS achieved a clearly visible limit of detection with cut-off values of 500, 5, and 0.5 μg L^-1 for NEO, PEN, and CAP, respectively within only 10 min. Such smartphone-based detection provided a limit of detection of 3.70 μg L^-1 for NEO, 0.10 μg L^-1 for PEN, and 0.008 μg L^-1 for CAP. The analysis of real samples by the developed MICS was well correlated with the enzyme-linked immunosorbent assay and liquid chromatography-mass spectrometry. The proposed MICS has the potential to be used for the simultaneous detection of NEO, PEN, and CAP with rapid, precise, and sensitive results.

31 Dec 2024·Virulence

Exogenous NADH promotes the bactericidal effect of aminoglycoside antibiotics against Edwardsiella tarda

Article

Author: Zhang, Ziyi ; Zheng, Yu ; Yang, Manjun ; Guo, Juan ; Zhong, Yilin ; Su, Yubin

The global surge in multidrug-resistant bacteria owing to antibiotic misuse and overuse poses considerable risks to human and animal health. With existing antibiotics losing their effectiveness and the protracted process of developing new antibiotics, urgent alternatives are imperative to curb disease spread. Notably, improving the bactericidal effect of antibiotics by using non-antibiotic substances has emerged as a viable strategy. Although reduced nicotinamide adenine dinucleotide (NADH) may play a crucial role in regulating bacterial resistance, studies examining how the change of metabolic profile and bacterial resistance following by exogenous administration are scarce. Therefore, this study aimed to elucidate the metabolic changes that occur in Edwardsiella tarda (E. tarda), which exhibits resistance to various antibiotics, following the exogenous addition of NADH using metabolomics. The effects of these alterations on the bactericidal activity of neomycin were investigated. NADH enhanced the effectiveness of aminoglycoside antibiotics against E. tarda ATCC15947, achieving bacterial eradication at low doses. Metabolomic analysis revealed that NADH reprogrammed the ATCC15947 metabolic profile by promoting purine metabolism and energy metabolism, yielding increased adenosine triphosphate (ATP) levels. Increased ATP levels played a crucial role in enhancing the bactericidal effects of neomycin. Moreover, exogenous NADH promoted the bactericidal efficacy of tetracyclines and chloramphenicols. NADH in combination with neomycin was effective against other clinically resistant bacteria, including Aeromonas hydrophila, Vibrio parahaemolyticus, methicillin-resistant Staphylococcus aureus, and Listeria monocytogenes. These results may facilitate the development of effective approaches for preventing and managing E. tarda-induced infections and multidrug resistance in aquaculture and clinical settings.

31 Dec 2024·Gut Microbes

Antibiotic-induced gut dysbiosis elicits gut-brain axis relevant multi-omic signatures and behavioral and neuroendocrine changes in a nonhuman primate model

Article

Author: Alsafwani, Zahraa Wajih ; Fischer, Anne ; Hassenstab, Haley R ; Conrin, Mackenzie ; Gerbers, Skyler ; French, Jeffrey A ; Thompson, Jennifer L ; Azadmanesh, Shayda ; Benson, Andrew K ; Briardy, Missy ; Alvarez, Sophie ; Jabenis, Aliyah ; Cooper, Kathryn ; Clayton, Jonathan B ; Suhr Van Haute, Mallory J ; Gasper, William ; Hayer, Shivdeep S

Emerging evidence indicates that antibiotic-induced dysbiosis can play an etiological role in the pathogenesis of neuropsychiatric disorders. However, most of this evidence comes from rodent models. The objective of this study was to evaluate if antibiotic-induced gut dysbiosis can elicit changes in gut metabolites and behavior indicative of gut-brain axis disruption in common marmosets (Callithrix jacchus) - a nonhuman primate model often used to study sociability and stress. We were able to successfully induce dysbiosis in marmosets using a custom antibiotic cocktail (vancomycin, enrofloxacin and neomycin) administered orally for 28 days. This gut dysbiosis altered gut metabolite profiles, behavior, and stress reactivity. Increase in gut Fusobacterium spp. post-antibiotic administration was a novel dysbiotic response and has not been observed in any rodent or human studies to date. There were significant changes in concentrations of several gut metabolites which are either neurotransmitters (e.g., GABA and serotonin) or have been found to be moderators of gut-brain axis communication in rodent models (e.g., short-chain fatty acids and bile acids). There was an increase in affiliative behavior and sociability in antibiotic-administered marmosets, which might be a coping mechanism in response to gut dysbiosis-induced stress. Increase in urinary cortisol levels after multiple stressors provides more definitive proof that this model of dysbiosis may cause disrupted communication between gut and brain in common marmosets. This study is a first attempt to establish common marmosets as a novel model to study the impact of severe gut dysbiosis on gut-brain axis cross-talk and behavior.

News (Medical) associated with Neomycin Sulfate

03 Oct 2024

·www.pharmaceutical-technology.com

A rational design approach to RNA targeting could replace large-scale screening

Maria Duca speaking at the ELRIG Drug Discovery conference in London, UK. Credit: Frankie Fattorini/ GlobalData As interest mounts in using RNA as a therapeutic target, a group at the Institute of Chemistry in Nice is overcoming the need for lengthy, expensive screening of candidate compounds with a rational design approach. Dr. Maria Duca, head of the Targeting of Nucleic Acids team, outlined her team’s novel approach to RNA-targeting drug discovery, in a presentation today (3 October) at the ELRIG Drug Discovery 2024 conference in London, UK. Duca pointed out, “If we look at currently marketed drugs, these mainly target proteins, but these proteins represent a very small percentage of what the human genome encodes. If we take into account non-coding RNAs as potential targets for drugs, we could really widen the landscape of current medicinal chemistry.” However, according to Duca, “The problem is that you don’t have many rational design methodologies in order to design your compound specific for a particular RNA target. So, everything is mostly based on screenings.” Instead of mass screenings, Duca and her team assemble and test novel molecular conjugates to be target-specific and therapeutically effective. Duca said some of the more promising candidates created using this approach have potential in oncological and infectious disease indications. See Also: Advancing Pharmaceutical Security: The Role of SECURtracers in On-Dose Authentication Healthcare Payers for the Pharmaceutical Industry Duca outlined the discovery process behind her team’s conjugate against microRNA-327 (miRNA-327), an oncogenic RNA implicated in gastric cancer. The team conjugated the aminoglycoside neomycin with different artificial nuclear bases. The conjugates produced were screened in vitro for their selectivity and inhibitive activity towards miRNA-327. Promising candidates from these screens could then be studied in vivo. In gastrinoma cancer cells, which are characterised by miRNA-327 overexpression, the team found the chosen candidates inhibited cell proliferation in a dose-dependent manner. Imaging the conjugate-RNA interactions allowed them to further refine these neomycin conjugates for their miRNA-327 affinity and inhibition. Through this same process of design, in vitro screening, in vivo testing, and further structural refinement of conjugates, Duca and her team have produced therapeutic candidates targeting other RNAs. For example, they built another library of candidates targeted against miRNA-21 which is overexpressed in glioblastoma, a type of brain cancer. Applying the same rational design process, researchers produced candidates that inhibited glioblastoma cell proliferation, in a way that was comparable with the efficacy of temozolomide, one of the few palliative treatments for glioblastoma, marketed as Kimozo / Kizfizo by Orphelia Pharma. mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Trilink . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper mRNA capping: low cost, high reward Are you aware of the latest mRNA capping techniques? The success of mRNA-based Covid vaccines has seen the technology boom in popularity – but capping is an essential part of the manufacturing process, and pharmaceutical firms face a range of choices on how to do it. This free whitepaper assesses differences in price, time, complexity and availability for the methods on offer – and provides essential insights on TriLink’s trailblazing CleanCap® approach. Fill in your details to find out more. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Trilink Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Trilink Thematic and that your personal data will be used as described in their Privacy Policy

VaccinemRNAsiRNA

23 Aug 2022

·www.prnewswire.com

Stud-RX Gives Texas Men Relief From Embarrassing ED Problems in the Lone Star State

HOUSTON, Aug. 22, 2022 /PRNewswire/ -- Stud-RX® is the first brand launched by "Isopharmic" company founded by Dr. J. David Hayes and partners in 2020. The innovative team sensed the need for a totally discreet platform where men can feel less vulnerable to discussing their intimate concerns. This telehealth application specializes in the treatment for erectile dysfunction. No more embarrassing appointments in primary care or urologists' office. No more muddling through a healthcare environment that impedes treatment. Men can get their erectile dysfunction questions answered, discuss options, and receive medications promptly, totally online, through a telehealth visit. All calls and messages are free and totally confidential. Continue Reading Erectile Dysfunction Treatments Online According to TrendStatistics.com, "Most ED patients are over the age of 40. Erectile dysfunction will happen to 33% of men by age 50, and erectile dysfunction will happen to 42% of men by age 60." Also, people are living longer, and many healthy, vibrant seniors express a growing concern about how they can continue to experience sexual pleasure with their spouse. Stud RX® has a team of top-notched, highly qualified health clinicians who can privately walk through a series of treatments with each client, making it a truly personalized experience. A compound can be made with the same active ingredients found in commercially available oral prescriptions. These compounds are made into different dosage forms or in strengths that the active ingredient is not typically available in. Happy customer, JD, posted these comments in his five-star review, "I really like having the choice when it comes to the medication that fits my needs." All visits include a digital provider consultation, customized medication, monthly refills, and medical support. All segments are focused and individually designed to improve erection and endurance. Stud-RX® offers four effective and safe customized plans to choose from. The rapid quarter horse, the long-acting thoroughbred, the rapid and long-acting mustang, and the rapid and long-acting stallion. Stud-RX® is an industry leader that is dedicated to its customers. They endeavor to provide prompt access to quality care and treatments, through their relationships with medical and pharmacy providers. Stud-RX® products are only available for Texas residents. They go the extra mile to meet the needs of each valued client and tout, "Our providers have the full spectrum of solutions (commercial and compounded) available for ED. Since we are local, we can ship or deliver the same day if the address is within 30 miles of a STUD-RX® HUB Pharmacy. We are committed to your success." For more information, please contact Annette Blaylock at phone: 619-333-1229 or Email: [email protected] or go to Website: . SOURCE Isopharmic LLC

20 Jul 2022

·www.sciencedaily.com

Antibiotics affect male and female gut microbiomes differently

In a new study, researchers found that antibiotics have sex-specific effects on the gut microbiome makeup of male and female laboratory rats. The findings could have implications for using the drugs in humans to treat or prevent bacterial infection. In a new study, researchers at Cedars-Sinai found that antibiotics have sex-specific effects on the gut microbiome makeup of male and female laboratory rats. The findings, published in the journal Frontiers in Microbiology, could have implications for using the drugs in humans to treat or prevent bacterial infection. "We found that giving the rats a multidrug antibiotic cocktail resulted in significant and sex-specific changes in both the stool, or large intestine, and the small bowel. For example, greater loss of the diversity of the microbes in both stool and small bowel was observed in the male rodents than in the females," said Ruchi Mathur, MD, the study's principal investigator. "Changes in the diversity of the gut microbiome could have a negative impact. Previous studies of intestinal health have demonstrated that overall microbial diversity promotes vitality and resilience, often making for a healthier gut," said Mathur, an endocrinologist. In the controlled study, investigators from the Cedars-Sinai Medically Associated Science and Technology (MAST) Program compared the composition of the gut microbes of the male and female rats before, during and after treatment with broad-spectrum antibiotics, including vancomycin, ampicillin, metronidazole, and neomycin. "We followed the rats for a period after the antibiotics were stopped and found that many of the sex-specific changes we observed during treatment remained. The constellation of microbes in the gut did not return to their original, pre-antibiotic compositions in either sex during the duration of the study," said research associate Gonzalo Parodi, first author of the paper. Some studies have identified sex-specific effects of antibiotics on the large bowel (stool) microbiome in mice. But Cedars-Sinai investigators emphasize that this is the first study to also examine changes in the small bowel microbiome induced by antibiotics and to also use male and female rats that had no significant differences in microbiome composition prior to treatment. "It is difficult to tease out the impact of the drugs if the lab animals' gut microbiomes are different to begin with. We used rats with similar gut profiles right out of the gate. This allowed us to pinpoint changes in the microbiomes of the male and female rats that could be attributed specifically to the impact of the antibiotics during and after exposure to the medicines," said Mark Pimentel, MD, director of the MAST program and a co-author of the study. More studies are needed using different combinations of antibiotics and exposure times. Investigators say if these findings hold true for humans, the research could have implications for the way antibiotics are prescribed. "Sex is a biological variable, and like any variable, it needs to be taken into consideration in basic and medical research. Currently, we consider factors such as kidney function and weight when dosing medications for patients. Depending on the results of further research, specifically in humans, the sex of patients may one day be an important consideration when prescribing antibiotics," said Mathur.

100 Deals associated with Neomycin Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Neomycin Sulfate	S01AA03 D06AX04 S02AA07 J01GB05 A07AA01 A01AB08 S03AA01 R02AB01 B05CA09	DB00452

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Infections	CN	Hubei Dongsheng Pharmaceutical Co. Ltd.	01 Jan 1984
Bacterial Infections	JP	Showa Yakuhin Kako Co., Ltd.	23 Dec 1966
Secondary infection	JP	Tayca Corp.	14 Oct 1964

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03557008 (CTgov)	Phase 4	Rabies	37	Rabies Vaccine+metronidazole+Neomycin Sulfate+Vancomycin (Rabies Vaccine With Antibiotics)	uhmayjxgwb(nnngoszlgv) = rhlmktbixf kmuwkgmika (nihbojzuto, hkehbxfehi - tknybbnmxa) View more	-	08 Jun 2023
				Rabies Vaccine (Rabies Vaccine)	uhmayjxgwb(nnngoszlgv) = zspcrqdzio kmuwkgmika (nihbojzuto, iepetfjnnb - eqinvmgsdj) View more
NCT02765256 (Holiday, CTgov)	Phase 2	Crohn Disease	8	Fluconazole+Promethazine+Polyethylene Glycol 3350+Neomycin+Ciprofloxacin+Vancomycin (Fluconazole)	axvafbznnr(ojvyaiwrxz) = sneuiogcqa fkmzmsctwr (xzmazjgaqr, hdwealbsjj - uvzmtyggmd) View more	-	08 Feb 2021
				Fluconazole placebo+Promethazine+Polyethylene Glycol 3350+Neomycin+Ciprofloxacin+Vancomycin (Placebo)	axvafbznnr(ojvyaiwrxz) = myqehdzpfp fkmzmsctwr (xzmazjgaqr, tyxtcgfxno - sgfojlegoh) View more
NCT02730962 (CTgov)	Phase 2	Metabolic Syndrome \| Prediabetic State	12	Fecal Microbiota Transplantation+Neomycin+Clindamycin+Vancomycin (Antibiotics Prior to FMT)	hzgmyqkwfz(kbhfgmekpk) = byyydsnxnh dnurvoofaa (vsihhfdmic, vktubgvrxr - jnsabcnavy) View more	-	20 Nov 2020
				Fecal Microbiota Transplantation (Placebo Prior to FMT)	hzgmyqkwfz(kbhfgmekpk) = isyuhooxwk dnurvoofaa (vsihhfdmic, ivikdftisy - kwmvgssagr) View more
ARVO2019	Not Applicable	Wound Infection	310	Topical Bacitracin Zinc+Neomycin Sulfate+Polymyxin B (Neosporin)	vvidtiqtte(uqllsmsdqc) = qozrtjxlsj ccrkximpnj (rxtuxqbeqd )	-	01 Jul 2019
				Gentamicin	vvidtiqtte(uqllsmsdqc) = spjthhfgvq ccrkximpnj (rxtuxqbeqd )
NCT02154061 (VAX-002, CTgov)	Not Applicable	Influenza, Human	33	IIV Flu Vaccine+metronidazole+Neomycin+Vancomycin (IIV Flu Vaccine With Antibiotics)	rvkhhuscki(pvnbanquxd) = djffszfoao vadntcvddp (vtzehymxdb, fwlhwgbmmo - hgcxnuunth) View more	-	27 Jun 2018
				IIV Flu Vaccine (IIV Flu Vaccine)	rvkhhuscki(pvnbanquxd) = grikfjvvdr vadntcvddp (vtzehymxdb, ismbvtcwkl - aumznyfesz) View more
UEGW	Not Applicable	-	-	bacitracin (Control)	mfdzbunzxl(oujvyzamyu) = bkdqtghrcw tlxewmehba (ghbespfbyy, 60.20)	-	01 Oct 2015
				Bacitracin and Neomycin	mfdzbunzxl(oujvyzamyu) = swwflcdawv tlxewmehba (ghbespfbyy, 25.84)
NCT00945334 (C-IBS, CTgov)	Not Applicable	Irritable Bowel Syndrome	37	Placebo+Neomycin (Group 1)	ngkbljogxz(rdnieajejo) = lphdiygbgg zlaiwewgok (iinpzddzip, aqwghzddla - cjtvlhmqam) View more	-	10 Aug 2015
				Neomycin+Rifaximin (Group 2)	ngkbljogxz(rdnieajejo) = ktunmmatpe zlaiwewgok (iinpzddzip, sylcsfwfkq - jyqoptmlcp) View more
Pubmed \| Dig Dis Sci	Not Applicable	Blind Loop Syndrome	98	Rifaximin	(cksuyhwnig) = dmevvzzwvq jrwwbptxcg (ofmuuzrrmr )	Positive	01 Jan 2008
				Neomycin	(cksuyhwnig) = aoqlqisanv jrwwbptxcg (ofmuuzrrmr )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis